Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company's product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. Novan, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Novan's stock rockets after positive trial results Shares of Novan Inc. NOVN, +32.69% rocketed 65% in premarket trade Wednesday, after the drugmaker announced positive results of a Phase 2 trial of its skin and nails treatment. Novan is developing an antifungal gel, SB208, for the treatment of superficial cutaneous fungal infections of the skin and nails, including tinea pedis, or athlete's foot, and onychomycosis. The company said SB208 deomonstrated "statistically significant effect" compared with vehicle in a clinical trial in patients with athlete's foot. " Our ability to deploy antimicrobial doses of nitric oxide in this trial gives us confidence to move forward in the development of a potential treatment for hard-to-treat infections like onychomycosis," said Chief Executive Nathan Stasko. http://www.marketwatch.com/story/novans-stock-rockets-after-positive-trial-results-2017-04-12
I didn't know there was a thread on NOVN..... as no many talk about it ..... I didn't look either yes that is the question today high (so far) is the resistance..... now it looks a bit tired see how it close .... IMO tomorrow could still be few waves.... btw big gap to close
